Pannysylvania Magazine

Hyderabad, India 5 September 2026 – According to Mordor Intelligence, the Biological Safety Testing Market size is estimated at USD 5.07 billion in 2026 and is projected to reach USD 8.78 billion by 2031, growing at a CAGR of 11.63% during the forecast period. The market is supported by expanding biopharmaceutical research, increasing development of cell and gene therapies, stricter contamination-control requirements, and growing outsourcing of quality-control activities to contract development and manufacturing organizations.

Biological safety testing is used to confirm that biologics, vaccines, and advanced therapies are free from contamination before release. Testing activities cover areas such as sterility, bioburden, endotoxin, mycoplasma, and adventitious virus detection, with requirements extending from cell-bank development through commercial manufacturing. The Biological Safety Testing Market growth is also being supported by the increasing complexity of advanced therapies and the need for validated testing processes across different stages of production.

Report Overview: https://www.mordorintelligence.com/industry-reports/global-biological-safety-testing-market-industry?utm_source=abnewswire

Biological Safety Testing Market Trends

Growing Demand from Cell and Gene Therapy Development

One of the most important Biological Safety Testing Market trends is the increasing demand for testing associated with cellular and gene therapies. These therapies involve complex manufacturing processes and require detailed safety assessments to identify potential contamination risks. The growing number of advanced therapy programs is therefore creating additional demand for specialized testing services and validated assays.

Cell and gene therapy programs can require extensive testing because of their complex manufacturing and release requirements. This is creating opportunities for laboratories that can provide viral safety, mycoplasma, sterility, and other testing services suited to advanced therapy workflows.

Increasing Focus on Regulatory Compliance

Stricter global requirements for contamination control are supporting the Biological Safety Testing industry. Regulatory authorities continue to place strong emphasis on safety testing, documentation, and validated methods for biologics and advanced therapies. These requirements encourage manufacturers to maintain comprehensive testing programs covering raw materials, intermediates, cell banks, and finished products.

The regulatory focus is also increasing interest in molecular and sequencing-based approaches for certain applications. Greater attention to viral safety and molecular characterization is creating demand for testing providers with specialized capabilities and quality systems that can support submissions across multiple markets.

Growing Outsourcing to CDMOs and Contract Laboratories

Outsourcing is another important factor supporting Biological Safety Testing Market growth. Biopharmaceutical companies are increasingly working with CDMOs and specialized laboratories for quality-control and safety testing rather than maintaining every testing capability internally.

External providers can offer specialized facilities, trained personnel, validated methods, and testing capacity across multiple programs. This is particularly useful for smaller biotechnology companies and developers working on complex therapies that require specialized safety testing infrastructure.

Rising Demand for Adventitious Virus Detection

Adventitious virus detection is gaining importance within the Biological Safety Testing Market as developers of advanced therapies place greater emphasis on viral safety. Testing for unwanted viral contamination is relevant across cell banks, biological materials, and manufacturing processes.

The growing use of viral vectors and other complex biological materials is increasing demand for testing services capable of detecting and characterizing potential viral contaminants. This is creating additional opportunities for specialized laboratories and testing providers.

Biological Safety Testing Market Segmentation

The Biological Safety Testing Market is segmented by product and service, test type, application, end user, and geography.

By Product & Service

• Products

• Reagents & Kits

• Instruments

• Single-Use Consumables

• Services

• Sterility Testing Services

• Endotoxin & Pyrogen Testing Services

• Cell Line Authentication & Characterisation

By Test Type

• Sterility Tests

• Bioburden Tests

• Endotoxin/LAL Tests

• Mycoplasma Detection

• Adventitious Virus Detection

By Application

• Recombinant Protein / Monoclonal Antibodies

• Vaccine And Therapeutics

• Cellular And Gene Therapy

• Blood And Blood-Based Therapy

• Other Application

By End User

• Biopharma & Biotech Companies

• Contract Development & Manufacturing Organisations

• Academic & Research Institutes

• Medical Device Manufacturers

By Geography

• North America

• United States

• Canada

• Mexico

• Europe

• Germany

• United Kingdom

• France

• Italy

• Spain

• Rest Of Europe

• Asia-Pacific

• China

• Japan

• India

• Australia

• South Korea

• Rest Of Asia-Pacific

• Middle East And Africa

• GCC

• South Africa

• Rest Of Middle East And Africa

• South America

• Brazil

• Argentina

• Rest Of South America

Biological Safety Testing Market Competitive Landscape

The competitive landscape of the Biological Safety Testing industry includes global testing laboratories, pharmaceutical service providers, laboratory technology companies, and specialized biological safety testing organizations. Companies are focusing on expanding testing capabilities, strengthening laboratory networks, and providing integrated testing services for biopharmaceutical and advanced therapy developers.

Key Players

• Eurofins Scientific

• Merck KGaA

• Promega Corporation

• Thermo Fisher Scientific

• Lonza Group

• Charles River Laboratories

• SGS SA

• BioMérieux SA

• Sartorius AG

• WuXi AppTec

• Nelson Labs

• Steris PLC

• Microbac Laboratories

• Pacific BioLabs

• Alcami Corporation

The market remains moderately concentrated, with leading providers using broad laboratory networks and specialized testing capabilities to serve customers across different regions and stages of pharmaceutical development.

Conclusion

The Biological Safety Testing Market forecast reflects continued demand for testing services and products that help pharmaceutical and biotechnology companies confirm the safety and quality of biologics, vaccines, and advanced therapies. Increasing development of cell and gene therapies, stricter contamination-control requirements, and growing outsourcing of quality-control activities are supporting market expansion.

As biopharmaceutical manufacturing becomes more complex, the Biological Safety Testing Market size is expected to benefit from greater demand for sterility testing, endotoxin analysis, mycoplasma detection, and adventitious virus testing. CDMOs and specialized contract laboratories are also expected to play a larger role as manufacturers seek external testing capabilities and specialized infrastructure.

Industry Related Reports

The Small Molecule Drug Discovery Market is expected to grow from USD 67.42 billion in 2026 to USD 103.06 billion by 2031, at an 8.86% CAGR, supported by advances in AI-driven drug discovery, computational chemistry, rising chronic disease burden, and regulatory fast-track programs.

https://www.mordorintelligence.com/industry-reports/small-molecule-drug-discovery-market?utm_source=abnewswire

The Pyrogen Testing Market is projected to expand from USD 1.73 billion in 2026 to USD 2.99 billion by 2031, at an 11.51% CAGR, driven by increasing biologics and pharmaceutical development, regulatory emphasis on product safety, and adoption of alternative testing methods.

https://www.mordorintelligence.com/industry-reports/pyrogen-testing-market?utm_source=abnewswir

The Peptide Drug Discovery Market is expected to reach USD 755.80 million by 2030 from USD 546.5 million in 2025, growing at a 6.70% CAGR, supported by advances in peptide therapeutics, growing investment in drug development, and the expanding application of peptides across therapeutic areas.

https://www.mordorintelligence.com/industry-reports/peptide-drug-discovery-market?utm_source=abnewswire

About Mordor Intelligence:

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

For any inquiries or to access the full report, please contact:

[email protected]

https://www.mordorintelligence.com/

Media Contact
Company Name: Mordor Intelligence Private Limited
Contact Person: Jignesh Thakkar
Email: Send Email
Phone: +1 617-765-2493
Address:11th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli
City: Hyderabad
State: Telangana 500008
Country: India
Website: https://www.mordorintelligence.com/